Breyanzi Becomes Fourth CAR T-Cell Therapy Reimbursed In England

 
• By Neena Brizmohun

A lower asking price from BMS and more insight into the benefits Breyanzi offers have convinced the health technology assessment institute, NICE, to reverse its rejection of the one-off treatment for large B-cell lymphoma.

3d illustration CAR T-cell attack cancer cell and healthy cells
Breyanzi is a CAR T-cell therapy for patients with large B-cell lymphoma (Shutterstock)

More from Health Technology Assessment

More from Government Payers